CN106008393A - 一种达沙替尼中间体的合成方法 - Google Patents
一种达沙替尼中间体的合成方法 Download PDFInfo
- Publication number
- CN106008393A CN106008393A CN201610408861.2A CN201610408861A CN106008393A CN 106008393 A CN106008393 A CN 106008393A CN 201610408861 A CN201610408861 A CN 201610408861A CN 106008393 A CN106008393 A CN 106008393A
- Authority
- CN
- China
- Prior art keywords
- formulas
- urea
- dasatinib
- copper nanoparticle
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 239000002067 L01XE06 - Dasatinib Substances 0.000 title claims abstract description 40
- 229960002448 dasatinib Drugs 0.000 title claims abstract description 40
- 238000010189 synthetic method Methods 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 29
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 27
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000004202 carbamide Substances 0.000 claims abstract description 15
- 238000006555 catalytic reaction Methods 0.000 claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 3
- 239000002105 nanoparticle Substances 0.000 claims description 20
- 229910052802 copper Inorganic materials 0.000 claims description 18
- 239000010949 copper Substances 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- FANSKVBLGRZAQA-UHFFFAOYSA-M dipotassium;sulfanide Chemical compound [SH-].[K+].[K+] FANSKVBLGRZAQA-UHFFFAOYSA-M 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 230000003197 catalytic effect Effects 0.000 claims description 6
- 239000012046 mixed solvent Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 4
- 239000007789 gas Substances 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 3
- -1 Epoxide acrylate Chemical class 0.000 claims description 2
- 229910052786 argon Inorganic materials 0.000 claims description 2
- 239000001307 helium Substances 0.000 claims description 2
- 229910052734 helium Inorganic materials 0.000 claims description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 2
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical class OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- ZFMRDDYYJJCBKC-UHFFFAOYSA-N 2-amino-1,3-thiazole-5-carboxylic acid Chemical compound NC1=NC=C(C(O)=O)S1 ZFMRDDYYJJCBKC-UHFFFAOYSA-N 0.000 abstract description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052794 bromium Inorganic materials 0.000 abstract description 2
- DPLVEEXVKBWGHE-UHFFFAOYSA-N potassium sulfide Chemical compound [S-2].[K+].[K+] DPLVEEXVKBWGHE-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000035126 Facies Diseases 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000002027 dichloromethane extract Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 4
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 0 CC1=C(*=C)C(Cl)=CCC1 Chemical compound CC1=C(*=C)C(Cl)=CCC1 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- WFNLHDJJZSJARK-UHFFFAOYSA-N 2-chloro-6-methylaniline Chemical compound CC1=CC=CC(Cl)=C1N WFNLHDJJZSJARK-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- NRJWWKBZGGKFNQ-UHFFFAOYSA-N CC(CC(C1)N)N=C1Cl Chemical compound CC(CC(C1)N)N=C1Cl NRJWWKBZGGKFNQ-UHFFFAOYSA-N 0.000 description 1
- RTPGHNHZWTXVJA-UHFFFAOYSA-N CC(CCC(CCl)=C)OC Chemical compound CC(CCC(CCl)=C)OC RTPGHNHZWTXVJA-UHFFFAOYSA-N 0.000 description 1
- YRMMNLNUIAORHO-YBEGLDIGSA-N CC(NC(C1)=NC(C)=NC1Cl)S/C(/C(Nc1c(C)cccc1C)=C)=C\N Chemical compound CC(NC(C1)=NC(C)=NC1Cl)S/C(/C(Nc1c(C)cccc1C)=C)=C\N YRMMNLNUIAORHO-YBEGLDIGSA-N 0.000 description 1
- GPLRZSYXUNMBLV-UHFFFAOYSA-N Cc(cccc1C)c1NC(c([s]1)cnc1Cl)=O Chemical compound Cc(cccc1C)c1NC(c([s]1)cnc1Cl)=O GPLRZSYXUNMBLV-UHFFFAOYSA-N 0.000 description 1
- ATFJWDIIKPSVOJ-UHFFFAOYSA-N Cc1cccc(C)c1N(Cc(cc1)ccc1OC)C(c([s]1)cnc1Cl)=O Chemical compound Cc1cccc(C)c1N(Cc(cc1)ccc1OC)C(c([s]1)cnc1Cl)=O ATFJWDIIKPSVOJ-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KLEYVGWAORGTIT-UHFFFAOYSA-N Clc1ncc[s]1 Chemical compound Clc1ncc[s]1 KLEYVGWAORGTIT-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- KDKGWGUUUVROTO-UHFFFAOYSA-N ON1CCNCC1 Chemical compound ON1CCNCC1 KDKGWGUUUVROTO-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003925 parecoxib sodium Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- GGNIKGLUPSHSBV-UHFFFAOYSA-N thiazole-5-carboxamide Chemical compound NC(=O)C1=CN=CS1 GGNIKGLUPSHSBV-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- ICJGKYTXBRDUMV-UHFFFAOYSA-N trichloro(6-trichlorosilylhexyl)silane Chemical compound Cl[Si](Cl)(Cl)CCCCCC[Si](Cl)(Cl)Cl ICJGKYTXBRDUMV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610408861.2A CN106008393B (zh) | 2016-06-09 | 2016-06-09 | 一种达沙替尼中间体的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610408861.2A CN106008393B (zh) | 2016-06-09 | 2016-06-09 | 一种达沙替尼中间体的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106008393A true CN106008393A (zh) | 2016-10-12 |
CN106008393B CN106008393B (zh) | 2018-03-20 |
Family
ID=57091106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610408861.2A Expired - Fee Related CN106008393B (zh) | 2016-06-09 | 2016-06-09 | 一种达沙替尼中间体的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106008393B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006008556A1 (en) * | 2004-07-22 | 2006-01-26 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Imidazole and thiazole derivatives as antiviral agents |
CN102180842A (zh) * | 2011-03-29 | 2011-09-14 | 河南省科学院化学研究所有限公司 | 一种2-氨基-δ2-噻唑啉-4-羧酸的合成方法 |
CN102942565A (zh) * | 2012-11-06 | 2013-02-27 | 江西天人生态股份有限公司 | 一类3,4-二氯异噻唑衍生物及其制备方法和用途 |
-
2016
- 2016-06-09 CN CN201610408861.2A patent/CN106008393B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006008556A1 (en) * | 2004-07-22 | 2006-01-26 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Imidazole and thiazole derivatives as antiviral agents |
CN102180842A (zh) * | 2011-03-29 | 2011-09-14 | 河南省科学院化学研究所有限公司 | 一种2-氨基-δ2-噻唑啉-4-羧酸的合成方法 |
CN102942565A (zh) * | 2012-11-06 | 2013-02-27 | 江西天人生态股份有限公司 | 一类3,4-二氯异噻唑衍生物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN106008393B (zh) | 2018-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vahdat et al. | Synthesis of polyhydroquinoline derivatives via a four-component Hantzsch condensation catalyzed by tin dioxide nanoparticles | |
Adib et al. | Efficient highly diastereoselective synthesis of 1, 8a-dihydro-7H-imidazo [2, 1-b][1, 3] oxazines | |
René et al. | Efficient syntheses of 2-fluoroalkylbenzimidazoles and-benzothiazoles | |
Asatkar et al. | Facile protocol for the synthesis of benzothiazole, benzoxazole and N-benzimidazole derivatives using rice husk derived chemically activated carbon | |
CN107573333B (zh) | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 | |
Chatterjee et al. | Dehydrative intramolecular nitrone cycloaddition in confined aqueous media: a green chemical route to cis-fused chromano [4, 3-c] isoxazoles | |
Bodke et al. | Synthesis, antibacterial and antitubercular activity of novel Schiff bases of 2-(1-benzofuran-2-yl) quinoline-4-carboxylic acid derivatives | |
WO2020076951A1 (en) | Pyrimidine and pyrazine hdac1,2 inhibitors | |
CN105985294A (zh) | 一种奥拉帕尼的制备方法 | |
Béguin et al. | Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor | |
WO2019167085A1 (en) | Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate | |
CN106008393A (zh) | 一种达沙替尼中间体的合成方法 | |
CN109422700A (zh) | 一种n-乙酰基喹喔啉-2-酰胺及其衍生物的合成方法 | |
WO2012058254A1 (en) | Benzimidazole inhibitors of leukotriene production | |
Yusuf et al. | Synthesis of some alkoxy based bisthiadiazolines | |
Yin et al. | An efficient method for the synthesis of disubstituted thioureas via the reaction of N, N′-di-Boc-substituted thiourea with alkyl and aryl amines under mild conditions | |
CN106117201A (zh) | 一种抗血栓药物阿哌沙班的制备方法 | |
CN101880249B (zh) | 一种合成叔丁基亚磺酰胺的工艺方法 | |
CN103275034A (zh) | 一类小分子cathepsin D抑制剂的制备方法 | |
CN103333133A (zh) | 一种Tubulysin家族化合物关键中间体TUV的合成方法 | |
CN103965203B (zh) | 一类咪唑[1,2-c]-喹唑啉-3(2H)-酮稠杂环化合物及其制备方法 | |
Chen et al. | A new 4-(2-methylquinolin-4-ylmethyl) phenyl P1′ group for the β-amino hydroxamic acid derived TACE inhibitors | |
CN105646288A (zh) | 一种氨基甲酸酯衍生物的制备方法 | |
CN104945287A (zh) | 一种脒的磺酸内盐化合物的合成方法 | |
CN113754605A (zh) | 一种含氮配体及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Yao Meiyan Inventor after: Shi Liying Inventor after: Yang Qihong Inventor before: Chen Linghao |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180211 Address after: 276399, No. 1, building No. 6, Yuquanlu Road, No. 70, Yinan County, Linyi, Shandong Province, 202 Applicant after: Yao Meiyan Applicant after: Shi Liying Applicant after: Yang Qihong Address before: 1 residential building, No. 443 Changjiang East Road, Huangdao District, Shandong, China, 1708, China, 266520 Applicant before: Chen Da bio tech ltd, Qingdao |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180320 Termination date: 20190609 |
|
CF01 | Termination of patent right due to non-payment of annual fee |